On Jun. 29, 2021, Altimmune announced phase 1 AdCOVID clinical trial data that showed AdCOVID appeared to be well tolerated with an overall adverse event profile similar to intranasal saline placebo. The Phase 1 trial evaluated the safety and immunogenicity of the intranasally administered vaccine candidate in approximately 80 healthy adult volunteers between the ages of 18 and 55.